Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.58 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.57 |
| ▸ | RARB | P10826 | 6/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.54 |
| ▸ | BAD | Q92934 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.53 |
| ▸ | RXRA | P19793 | 1/20 | 0.53 |
| ▸ | RXRB | P28702 | 1/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.53 |
| ▸ | BCL2 | P10415 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1853914 | 0.98 | HRH3 (0.58) | HRH3TAAR1LOXL2RARBCA12 | |
| Aminomethylbenzoic Acid SCHEMBL9344424 | 0.93 | ALDH1A1 (0.60) | LOXL2CA12CA1CA2CA9 | |
| Aminomethylbenzoic Acid SCHEMBL38758 | 0.93 | ALDH1A1 (0.60) | LOXL2CA12CA1CA2CA9 | |
| Aminomethylbenzoic Acid SCHEMBL7428232 | 0.91 | ALDH1A1 (0.58) | LOXL2CA12CA1CA2CA9 | |
| Aminomethylbenzoic Acid SCHEMBL1206230 | 0.91 | ALDH1A1 (0.58) | LOXL2CA12CA1CA2CA9 | |
| Aminomethylbenzoic Acid SCHEMBL28342619 | 0.91 | ALDH1A1 (0.58) | LOXL2CA12CA1CA2CA9 | |
| Aminomethylbenzoic Acid SCHEMBL1567841 | 0.91 | ALDH1A1 (0.58) | LOXL2CA12CA1CA2CA9 | |
| Aminomethylbenzoic Acid SCHEMBL11755138 | 0.89 | ALDH1A1 (0.61) | LOXL2RARBALDH1A1HDAC3HDAC6 | |
| Aminomethylbenzoic Acid SCHEMBL29271526 | 0.87 | ALDH1A1 (0.59) | LOXL2RARBALDH1A1HDAC3HDAC6 | |
| SCHEMBL26112100 | 0.87 | SRD5A2 (0.58) | LOXL2CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666979-B2 | polyvalent targeting ligands that bind to cells used for diagnosis of diseases sensitivity to angiogenesis factor | BRACCO INTERNATIONAL B.V. (NL) | 2010-02-23 | — | — | US | claimed |
| EP-1778299-A4 | METHODS FOR PREPARING MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INT BV (NL) | 2009-08-26 | — | — | EP | claimed |
| EP-1778299-A2 | METHODS FOR PREPARING MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2007-05-02 | — | — | EP | claimed |
| WO-2006096207-A2 | METHODS FOR PREPARING MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2006-09-14 | — | — | WO | claimed |
| US-20050147555-A1 | Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same | BRACCO SUISSE SA (CH) | 2005-07-07 | — | — | US | claimed |
| WO-2023196898-A1 | BETA GLOBIN MIMETIC PEPTIDES AND THEIR USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-10-12 | — | — | WO | disclosed |
| CN-106795092-B | Epoxy ester compound, cellulose ester resin composition, optical film and liquid crystal display device | DIC株式会社 | 2019-05-17 | — | — | CN | disclosed |
| CN-105209942-B | Phase retardation film, polarizer and liquid crystal display device | 柯尼卡美能达株式会社 | 2018-01-30 | — | — | CN | disclosed |
| CN-105579874-B | Resin composition for optical material, optical thin film and liquid crystal display device | DIC株式会社 | 2017-09-05 | — | — | CN | disclosed |
| CN-106795092-A | Epoxy ester compound, cellulose ester resin composition, optical film and liquid crystal display device | DIC株式会社 | 2017-05-31 | — | — | CN | disclosed |
| CN-106468798-A | Phase retardation film, polaroid and liquid crystal indicator | 柯尼卡美能达株式会社 | 2017-03-01 | — | — | CN | disclosed |
| CN-105579874-A | Resin composition for optical materials, optical film and liquid crystal display device | DAINIPPON INK & CHEMICALS | 2016-05-11 | — | — | CN | disclosed |
| EP-1778299-A4 | METHODS FOR PREPARING MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INT BV (NL) | 2009-08-26 | — | — | EP | disclosed |
| WO-2009052078-A1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
| EP-1778299-A2 | METHODS FOR PREPARING MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006096207-A2 | METHODS FOR PREPARING MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2006-09-14 | — | — | WO | disclosed |
| US-20050147555-A1 | Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same | BRACCO SUISSE SA (CH) | 2005-07-07 | — | — | US | disclosed |
| US-20050124656-A1 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) | APPLIED RESEARCH SYSTEMS ARS (NL) | 2005-06-09 | — | — | US | disclosed |
| EP-1470102-A1 | SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | Applied Research Systems ARS Holding N.V. (AN) | 2004-10-27 | — | — | EP | disclosed |
| WO-2003064376-A1 | SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050147555-A1 | Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same | LDHB, FPGS, MTHFD2 | HRH3 2716/4885TAAR1 4205/4885LOXL2 3789/4885 |
| US-20050124656-A1 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) | PTPRS, PTPA, PTPMT1 | HRH3 3629/4885TAAR1 1657/4885LOXL2 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.